HAOHAI BIOTEC (06826): Multifocal aspheric intraocular lens products have obtained medical device registration certificates.
Haohai Biotechnology (06826) announced that its wholly-owned subsidiary Shanghai Haohai Biotechnology Co., Ltd. ("the Company") recently received the "Medical Device Registration Certificate of the People's Republic of China" issued by the National Medical Products Administration for its multifocal non-spherical artificial crystalline lens product (hereinafter referred to as "the product") produced by Henan Universe Artificial Crystalline Lens Research Co., Ltd.
HAOHAI BIOTEC (06826) announced that its wholly-owned subsidiary, Henan Universe Artificial Crystalline Lens Research Co., Ltd. (hereinafter referred to as the "Company"), recently received the "Medical Device Registration Certificate of the People's Republic of China" issued by the National Medical Products Administration for its multifocal non-spherical artificial crystalline lens product (hereinafter referred to as "this product").
This product is the world's first multifocal artificial crystalline lens based on the patented technology of FOURSEMI harmonic five-focus diffraction, which can achieve more efficient light energy distribution, improve light energy utilization, and enhance the visual acuity of traditional trifocal artificial crystalline lens, making the vision in the far intermediate area, intermediate distance area, and intermediate near area more continuous and smooth.
The approval of this product further enhances the company's product layout in high-end artificial crystalline lenses. The company has formed a complete matrix covering ordinary spherical single-focus products to high-end multifocal and continuous range artificial crystalline lens products, which will help enhance the company's competitiveness in the high-end refractive cataract field and promote the development of domestic artificial crystalline lenses towards higher technological levels and higher added value.
Related Articles
.png)
CICC (03908): Decides to exercise the redemption right of the issuer "21 China Gold Y2"

Shenghe Jingwei (688820.SH) IPO priced at 19.68 yuan per share, with subscription opening on April 9th.

Etek (603293.SH): The final online subscription rate is about 0.0247%.
CICC (03908): Decides to exercise the redemption right of the issuer "21 China Gold Y2"
.png)
Shenghe Jingwei (688820.SH) IPO priced at 19.68 yuan per share, with subscription opening on April 9th.

Etek (603293.SH): The final online subscription rate is about 0.0247%.

RECOMMEND

Hong Kong Stocks Surge! Buying Opportunity Or Wait And See? Analysts Provide Comprehensive Interpretation
02/04/2026

Narrative Drives Everything As China’s AI Newcomers Enter An Era Of Extreme Volatility, Retail Investors Flood In
02/04/2026

Fund Cohort Stocks Rally As Institutional Confidence In Hong Kong Equities Shows Signs Of Repair
02/04/2026


